Pacific Biosciences' Q4'24 results missed estimates. Growth in genetic data usage noted, but research funding uncertainties ...

Pacific Biosciences of California (NASDAQ:PACB – Get Free Report) had its price target dropped by research analysts at The ...

In a report released today, David Westenberg from Piper Sandler reiterated a Hold rating on Pacific Biosciences (PACB – Research Report), with ...

Morgan Stanley analyst Tejas Savant maintained a Hold rating on Pacific Biosciences (PACB – Research Report) today and set a price target of ...

StockNews.com upgraded shares of Pacific Biosciences of California (NASDAQ:PACB – Free Report) to a sell rating in a research note issued to investors on Tuesday morning. Other research analysts have ...

In the last three months, 4 analysts have published ratings on Pacific Biosciences (NASDAQ:PACB), offering a diverse range of perspectives from bullish to bearish. In the table below, you'll find ...

For the quarter ended December 2024, Pacific Biosciences of California (PACB) reported revenue of $39.22 million, down 32.8% over the same period last year. EPS came in at -$0.20, compared to -$0.27 ...

Q4 2024 Earnings Call Transcript February 13, 2025 Pacific Biosciences of California, Inc. beats earnings expectations. Reported EPS is $0.51, expectations were $-0.2. Operator: Good day. And welcome ...

MENLO PARK, Calif. (AP) — MENLO PARK, Calif. (AP) — Pacific Biosciences of California Inc. (PACB) on Thursday reported fourth-quarter profit of $3.6 million. The Menlo Park, California-based company ...

Full Year 2024 Results Key Financial Results Revenue: US$154.0m ...

Market forces rained on the parade of Pacific Biosciences of California, Inc. ( NASDAQ:PACB ) shareholders today, ...